132 related articles for article (PubMed ID: 30995685)
1. The combination of 13N-ammonia and 18F-FDG PET/CT in the identification of metabolic phenotype of primary human brain tumors.
Yi C; Shi X; Yu D; Luo G; Zhang B; He Q; Zhang X
Nuklearmedizin; 2019 Jun; 58(3):272-278. PubMed ID: 30995685
[TBL] [Abstract][Full Text] [Related]
2. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by
Ding L; Zhang F; He Q; Li Z; Shi X; Li R; Zhang X
BMC Cancer; 2020 Jun; 20(1):564. PubMed ID: 32552842
[TBL] [Abstract][Full Text] [Related]
5. One-day protocol for
Chang Y; Donglan Y; Xinchong S; Ganhua L; Bing Z; Yao L; Rutong Z; Qiao H; Xiangsong Z
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(2):68-74. PubMed ID: 32005511
[TBL] [Abstract][Full Text] [Related]
6. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess.
Shi X; Yi C; Wang X; Zhang B; Chen Z; Tang G; Zhang X
Clin Nucl Med; 2015 Mar; 40(3):195-9. PubMed ID: 25546194
[TBL] [Abstract][Full Text] [Related]
7. Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.
Khangembam BC; Karunanithi S; Sharma P; Kc SS; Kumar R; Julka PK; Kumar R; Bal C
Neuroradiology; 2014 Oct; 56(10):893-902. PubMed ID: 24989883
[TBL] [Abstract][Full Text] [Related]
8. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas.
Shi X; Liu Y; Zhang X; Yi C; Wang X; Chen Z; Zhang B
Clin Nucl Med; 2013 Jul; 38(7):522-6. PubMed ID: 23698463
[TBL] [Abstract][Full Text] [Related]
9. Identify glioma recurrence and treatment effects with triple-tracer PET/CT.
Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z
BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of (13)N-NH (3) PET in the evaluation of brain lesions that are hypometabolic on (18)F-FDG PET.
Xiangsong Z; Weian C; Dianchao Y; Xiaoyan W; Zhifeng C; Xiongchong S
J Neurooncol; 2011 Oct; 105(1):103-7. PubMed ID: 21503829
[TBL] [Abstract][Full Text] [Related]
11. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pathology and survival by FDG PET in gliomas.
Padma MV; Said S; Jacobs M; Hwang DR; Dunigan K; Satter M; Christian B; Ruppert J; Bernstein T; Kraus G; Mantil JC
J Neurooncol; 2003 Sep; 64(3):227-37. PubMed ID: 14558598
[TBL] [Abstract][Full Text] [Related]
13. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
14. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
15. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report.
Xiangsong Z; Xingchong S; Chang Y; Xiaoyan W; Zhifeng C
Clin Nucl Med; 2011 Nov; 36(11):1003-6. PubMed ID: 21975388
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of
Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
[TBL] [Abstract][Full Text] [Related]
18. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer.
Yi C; Yu D; Shi X; Zhang X; Luo G; He Q; Zhang X
Nucl Med Commun; 2016 Mar; 37(3):239-46. PubMed ID: 26588068
[TBL] [Abstract][Full Text] [Related]
19. Is integrated 18F-FDG PET/MRI superior to 18F-FDG PET/CT in the differentiation of incidental tracer uptake in the head and neck area?
Schaarschmidt BM; Gomez B; Buchbender C; Grueneisen J; Nensa F; Sawicki LM; Ruhlmann V; Wetter A; Antoch G; Heusch P
Diagn Interv Radiol; 2017; 23(2):127-132. PubMed ID: 28089955
[TBL] [Abstract][Full Text] [Related]
20. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
